Pfizer of the United States said on September 20 that the new coronavirus pneumonia (COVID-19) vaccine jointly developed by it and the German biotech company (BioNTech) is effective for children aged 5 to 11.
Pfizer intends to submit data to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible, seeking approval for emergency use authorization.
The Pfizer vaccine was jointly developed by the American pharmaceutical company Pfizer and the German biotech company (BioNTech).
Its product name in China is "Comirnaty" (Comirnaty).
Pfizer: The picture shows a girl in Kentucky, USA, watching her grandmother receive Pfizer's new crown vaccine on April 26.
(Getty)
According to Pfizer, the results of clinical trials conducted by researchers on 2,200 children aged 5 to 11 years have shown that the vaccine is safe and appears to trigger a strong immune response.
During the trial period, the dose inoculated in children was one-third of that in adolescents and adults.
The first and second needles were injected 3 weeks apart.
If the U.S. Food and Drug Administration (FDA) approves the application at the same time as it approves the vaccine for 12 to 15-year-olds, children 5 to 11 years old may be vaccinated on Halloween.
Pfizer Vaccine | American infectious disease expert Fauci: mRNA vaccine requires 3 doses of new coronary pneumonia | British media: The United States or October authorized Pfizer vaccine for children aged 5 to 11 years of new coronary pneumonia | New Zealand's first death case or vaccination Pfizer vaccine related to new coronary pneumonia | Pfizer: is developing a vaccine specifically for the Delta variant virus strain
It is worth noting that the two companies did not disclose some details about the trial, including among the children who participated in the trial, whether any of the children who participated in the trial had rare side effects after vaccination, that is, myocarditis (Myocarditis) or pericarditis (Pericarditis). .
The Centers for Disease Control and Prevention (CDC) of the United States is closely monitoring the occurrence of these problems in people receiving mRNA vaccines.
The CDC said it mostly occurs in adolescents and young adults, especially men, and it occurs more often within a few days after the second dose.
According to the CDC, after myocarditis or pericarditis develops after vaccination, patients will generally recover quickly after receiving treatment and rest.